Pomerantz LLP Launches Investigation Into Emergent BioSolutions

The investigation centers on disclosures made on August 5, 2026, when Emergent reported a $191.3 million non-cash impairment charge linked to its NARCAN asset group. This write-down contributed to a GAAP net loss of $180.2 million for the quarter ending June 30. Alongside the loss, management slashed full-year revenue guidance by approximately 10.8%, citing heightened market competition that threatened both near-term performance and asset valuations.

Following these announcements, Emergent’s stock plummeted by $2.23, closing at $5.31 on August 6. Investors holding shares during this period are encouraged to contact Danielle Peyton at Pomerantz LLP to discuss potential participation in a class action suit. The firm, founded by Abraham L. Pomerantz, specializes in securities litigation and corporate misconduct, maintaining offices across the U.S. and Europe.